Sequential use of targeted agents in the treatment of renal cell carcinoma

被引：48

作者：

Hutson, Thomas E. ^{[1
]}

Bukowski, Ronald M. ^{[2
]}

Cowey, C. Lance

Figlin, Robert ^{[3
]}

Escudier, Bernard ^{[4
]}

Sternberg, Cora N. ^{[5
]}

机构：

[1] Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Dallas, TX 75246 USA

[2] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA

[3] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

[4] Inst Gustave Roussy, Villejuif, France

[5] San Camillo Forlanini Hosp, Dept Med Oncol, Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2011年 / 77卷 / 01期

关键词：

Renal-cell carcinoma; Tyrosine kinase inhibitor; mTOR inhibitor; Sequential therapy; Everolimus; Sorafenib; Sunitinib; Pazopanib; PHASE-II TRIAL; RETROSPECTIVE ANALYSIS; DOSE INTERLEUKIN-2; INTERFERON-ALPHA; SUNITINIB MALATE; DOUBLE-BLIND; SORAFENIB; CANCER; THERAPY; BEVACIZUMAB;

D O I：

10.1016/j.critrevonc.2010.07.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sequential use of targeted therapies is a common practice in the treatment of advanced renal cell carcinoma (RCC) that extends disease control beyond the benefit of single therapies. After disease progression on one agent, treatment with a second targeted agent as subsequent-line therapy provides disease control and additional progression-free survival. The most effective sequence of targeted agents has yet to be determined. Results from the only trial of sequenced targeted agents support the use of mammalian target of rapamycin inhibitors after resistance develops to vascular endothelial growth factor (VEGF) inhibitors. Preliminary data suggest an antitumor effect of VEGF-targeted therapy in RCC, despite prior exposure to other VEGF-targeted therapies. The safety and efficacy of sequential therapies are currently under investigation; the optimal sequence may vary among patients to accommodate comorbid conditions or different disease stages. The current evidence supporting sequential use of targeted agents in RCC is presented in this review. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：49 / 63

页数：15

共 103 条

[1] Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor [J].

Albert, DH ;

Tapang, P ;

Magoc, TJ ;

Pease, LJ ;

Reuter, DR ;

Wei, RQ ;

Li, JL ;

Guo, J ;

Bousquet, PF ;

Ghoreishi-Haack, NS ;

Wang, B ;

Bukofzer, GT ;

Wang, YC ;

Stavropoulos, JA ;

Hartandi, K ;

Niquette, AL ;

Soni, N ;

Johnson, EF ;

McCall, JO ;

Bouska, JJ ;

Luo, Y ;

Donawho, CK ;

Dai, YJ ;

Marcotte, PA ;

Glaser, KB ;

Michaelides, MR ;

Davidsen, SK .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :995-1006

[2]

[Anonymous], Study to Compare Tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma

[3]

[Anonymous], J CLIN ONCOL

[4] Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference [J].

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Escudier, Bernard J. ;

Figlin, Robert A. ;

Hudes, Gary H. ;

Kaelin, William G., Jr. ;

Linehan, W. Marston ;

McDermott, David F. ;

Mier, James W. ;

Pedrosa, Ivan ;

Rini, Brian I. ;

Signoretti, Sabina ;

Sosman, Jeffrey A. ;

Teh, Bin Tean ;

Wood, Christopher G. ;

Zurita, Amado J. ;

King, Laura .

CANCER, 2009, 115 (10) :2247-2251

[5] The medical treatment of metastatic renal cell cancer in the elderly: Position paper of a SIOG Taskforce [J].

Bellmunt, Joaquim ;

Negrier, Sylvie ;

Escudier, Bernard ;

Awada, Ahmad ;

Aapro, Matti .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (01) :64-72

[6] Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[7]

Bhargava P, 2009, J CLIN ONCOL, V27

[8] Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT [J].

Blanke, Charles D. ;

Demetri, George D. ;

von Mehren, Margaret ;

Heinrich, Michael C. ;

Eisenberg, Burton ;

Fletcher, Jonathan A. ;

Corless, Christopher L. ;

Fletcher, Christopher D. M. ;

Roberts, Peter J. ;

Heinz, Daniela ;

Wehre, Elisabeth ;

Nikolova, Zariana ;

Joensuu, Heikki .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :620-625

[9] Sunitinib therapy for patients with advanced renal cell carcinoma (aRCC): Analysis for safety and activity on single institution experience-Prolonged overall survival [J].

Castellano, D. E. ;

Sepulveda, J. ;

Diaz Padilla, I. ;

Coronado, C. ;

Holgado, E. ;

Garcia Escobar, I. ;

DelaRosa, F. ;

Villacampa, F. ;

Cortes-Funes, H. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[10] Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma [J].

Cho, Daniel C. ;

Puzanov, Igor ;

Regan, Meredith M. ;

Schwarzberg, Talya ;

Seery, Virginia ;

Lee, Mee-Young ;

Liu, Vivian ;

Bhatt, Rupal ;

Koon, Henry ;

Mier, James W. ;

Sosman, Jeffrey A. ;

Atkins, Michael B. ;

McDermott, David F. .

JOURNAL OF IMMUNOTHERAPY, 2009, 32 (02) :181-185

← 1 2 3 4 5 6 7 8 9 10 →